| 01st week of 2016 patent applcation highlights part 8 |
| Patent application number | Title | Published |
|---|
| 20160000707 | METHODS OF INHIBITING CATARACTS AND PRESBYOPIA - Described herein are methods of inhibiting or reversing the progression of cataract formation or presbyopia in an eye by administering a γ-crystallin charge masking agent. Both presbyopia and cataracts are caused by aggregation of the soluble crystalline lens proteins called the crystallins. | 2016-01-07 |
| 20160000708 | SOFT, CHEWABLE AND ORALLY DISSOLVABLE AND/OR DISINTEGRABLE PRODUCTS - A soft, chewable and orally dissolvable and/or disintegrable product includes a biopolymer-sugar based matrix and botanical powder dispersed throughout the biopolymer-sugar based matrix. The biopolymer-sugar based matrix includes at least one biopolymer, at least one sugar and optional additives. Soft, chewable and orally dissolvable and/or disintegrable product can also include flavor beads. | 2016-01-07 |
| 20160000709 | DRY POWDER INHALER FORMULATIONS COMPRISING SURFACE-MODIFIED PARTICLES WITH ANTI-ADHERENT ADDITIVES - The present invention is concerned with a refinement of the processing of particles that are to form a dry powder formulation which is to be administered to the lung using a dry powder inhaler (DPI) device. In particular, the present invention provides the processing of particles of active material and particles of carrier material in the presence of additive material to provide a powder composition which exhibits excellent powder properties and which is economical to produce. | 2016-01-07 |
| 20160000710 | MILK-DERIVED MICROVESICLE COMPOSITIONS AND RELATED METHODS - A composition is provided that comprises a therapeutic agent encapsulated by a milk-derived microvesicle. The compositions can include therapeutic agents such as phytochemical agents or chemotherapeutic agents, while the milk-derived microvesicle can be derived from raw milk or colostrum. Further provided are methods for isolating a microvesicle that includes the steps of obtaining an amount of milk, and subjecting the milk to a series of sequential centrifugations configured to yield greater than about 300 mg of microvesicle protein per 100 ml of milk. Methods of modifying an immune response and treating a cancer in which a milk-derived microvesicle composition is administered are also provided. | 2016-01-07 |
| 20160000711 | Stabilized Granules Containing Glyceryl Trinitrate - Solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight % glyceryl trinitrate, at least one carrier material, and at least one substance that reduces the volatility of the GTN, whereby this substance is a non-volatile ester stabilizer. | 2016-01-07 |
| 20160000712 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2016-01-07 |
| 20160000713 | SOLVENT EXTRACTION FROM BIODEGRADABLE MICROPARTICLES - Embodiments may include a method for reducing a solvent concentration in a plurality of microparticles. The method may involve contacting a mixture including the plurality of microparticles and the solvent with water to form an aqueous suspension. A first portion of the solvent may dissolve into the water of the aqueous suspension to reduce the solvent concentration in the plurality of microparticles from a first solvent concentration in the mixture to a second solvent concentration in the aqueous suspension. The method may also include transferring the aqueous suspension to a concentration unit that may further reduce the solvent concentration from the second solvent concentration to a third solvent concentration. The method may further include transferring a microparticle concentrate with the third solvent concentration to a washing unit to form an amalgam of washed microparticles with a fourth solvent concentration. The method may also include drying the amalgam of washed microparticles. | 2016-01-07 |
| 20160000714 | CURCUMIN SOLID LIPID PARTICLES AND METHODS FOR THEIR PREPARATION AND USE - Solid lipid particles comprising a lipid hydrophobic matrix and from about 5 wt. % to about 30 wt. % of curcumin, and methods of making and treatment thereof. | 2016-01-07 |
| 20160000715 | Combinations of Oral Medicaments Bonded by a Wrapping - An oral pharmaceutical dosage form is provided which contains at least two medicaments, in which form the medicaments on the one hand are brought together in a leakproof and in-vivo water soluble wrapping and on the other hand are separated so that the active principle of the combined medicaments cannot come into contact with one another. At least one of the medicaments can be chosen from the following therapeutic classes: non-steroidal anti-inflammatory drug (NSAID), proton pump inhibitor (PPI), beta-blocker, statin, conversion enzyme inhibitor (CEI), biguanide, myorelaxant, calcium inhibitor, corticoid, antidepressant, benzodiazepine, non-atropine-like intestinal transit retarder, intestinal antibacterial, and the following therapeutic molecules: spironolactone, propranolol, clarithromycin, amoxycillin, low-dose acetylsalicylic acid, potassium, and clopidogrel. | 2016-01-07 |
| 20160000716 | METHOD OF TREATING VITAMIN B12 DEFICIENCY - The present invention relates generally to Vitamin B12 pharmaceutical composition and method of using the same for the treatment of Vitamin B12 deficiency and the various disorders that are related to such deficiency. In particular embodiments, the present invention is directed towards treatment methods comprising sublingual or buccal administration of a Vitamin B12 composition useful in the practice of such treatment. The present invention features compositions that include one or more Vitamin B 12 compounds, propylene glycol, a solid adsorbent and a solid water-soluble excipient, wherein the Vitamin B 12 compounds are in a propylene glycol solution. | 2016-01-07 |
| 20160000717 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2016-01-07 |
| 20160000718 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2016-01-07 |
| 20160000719 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2016-01-07 |
| 20160000720 | Pharmaceutical compositions comprising Tadalafil - Pharmaceutical compositions comprising tadalafil or a pharmaceutically acceptable salt thereof are provided. The present invention also relates to a process for preparation of pharmaceutical compositions comprising tadalafil or a pharmaceutically acceptable salt thereof. The present invention also relates to method of administering the compositions comprising tadalafil in a subject in need thereof. | 2016-01-07 |
| 20160000721 | GASTRO-RETENTIVE FORMULATIONS - The present invention relates to pharmaceutical compositions of the poorly soluble drugs, and pharmaceutically acceptable salts thereof, in a controlled-release gastric retained oral dosage form. Such compositions are formulated so as to deliver the majority of the incorporated drug into the stomach and upper gastrointestinal tract, with restricted drug delivery in the lower gastrointestinal tract. The dosage forms have multiple layers including an active layer with a first swellable polymer with raltegravir incorporated therein and a non-active layer with a second swellable polymer having a similar molecular weight or a higher molecular weight as the swellable polymer in the active layer. | 2016-01-07 |
| 20160000722 | DOSAGE FORM FOR CINEOLE - The invention relates to a dosage form containing cineole for peroral application in capsule form, wherein the dosage form containing cineole is designed as a capsule-in-capsule system, wherein the capsule-in-capsule system has an outer capsule (outside capsule) having an outer capsule shell and a plurality of inner capsules (inside capsules) located in the outer capsule, wherein the inner capsules are completely enclosed by the capsule shell of the outer capsule and the inner capsules are designed as microcapsules, which each contain the active ingredient 1,8-cineole. The invention further relates to the production and use of said dosage form containing cineole. | 2016-01-07 |
| 20160000723 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2016-01-07 |
| 20160000724 | CONTROLLED RELEASE NANOPARTICLES AND METHODS OF USE - Provided herein are nanoparticles that include a lipid layer and a compartment surrounded by the lipid layer. The lipid layer may include a lipid and a lipoprotein. The lipid may include a POPE lipid covalently attached to a hydrophilic polymer by a disulfide bond. The lipoprotein may include a trigger protein. The concentration of the first lipid may be between 1 mol % and 30 mol %. The disulfide bond of the first lipid is stable under conditions that include 10% human serum and is broken under conditions that include 50 micromolar glutathione. The hydrophilic polymer may include a PEG molecule. The trigger protein may include an amino acid repeat region, such as (GPX)n. The trigger protein may include a peptide bond that is cleaved by a gelatinase (e.g., gelatinase-B protease), or a member of the ADAM family of proteases (e.g., ADAM10 protease). Also provided are methods of using the nanoparticles. | 2016-01-07 |
| 20160000725 | Nanoparticle- and Drug-Containing Polymersomes for Medical Applications - Provided are polymersomes for co-delivery of hydrophobic metallic nanoparticles and pharmaceutical agents and suspensions of such polymersomes. Also provided are methods of making such polymersomes and suspensions of polymersome and methods of using the same to treat diseases or conditions. | 2016-01-07 |
| 20160000726 | PURIFIED THERAPEUTIC NANOPARTICLES AND PREPARATION METHODS THEREOF - Purified therapeutic nanoparticles are provided herein. Such nanoparticles comprise an active pharmaceutical ingredient and human serum albumin, wherein the weight ratio of human serum albumin to the active ingredient in the therapeutic nanoparticles is from 0.01:1 to 1:1, and wherein the nanoparticles are substantially free of free human serum albumin that is not incorporated in the nanoparticles. The present disclosure also provides pharmaceutical compositions that comprise the purified therapeutic nanoparticles and are also substantially free of free human serum albumin. Methods for preparing and using the purified therapeutic nanoparticles and compositions thereof are also provided. | 2016-01-07 |
| 20160000727 | BETA CAROTENE PREPARATION - An aqueous emulsion for use in veterinary medicine which contains beta carotene and can be administered parenterally from a sterile multi-dose container contains acetylcysteine in an amount of between 1 and 8 wt.-% as a substance which stabilizes the emulsion and protects preservatives and beta carotene from being decomposed. The beta carotene-containing emulsion can additionally contain at least one antioxidant and at least one preservative. As the antioxidant, ascorbyl palmitate or alpha-tocopherol can be added. The emulsion can further contain a solubilizer, for example isopropyl myristate or Solutol® HS 15. | 2016-01-07 |
| 20160000728 | Multiparticulate L-Menthol Formulations and Related Methods - An L-menthol pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core and an enteric coating over the core. The core includes an L-menthol source that is at least 80% pure L-menthol. The dosage form may be used to treat gastrointestinal disorders, such as irritable bowel syndrome. | 2016-01-07 |
| 20160000729 | NEURONAL CIRCUIT-DEPENDENT NEUROPROTECTION BY INTERACTION BETWEEN NICOTINIC RECEPTORS - A method of inhibiting excitotoxicity by indirectly activating α4β2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed Inhibitors of α7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate α4β2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis. | 2016-01-07 |
| 20160000730 | MANAGING OSTEOPOROSIS WITH HMW PEG - The present invention relates to the administration of compositions comprising polyethylene glycol, for improving the general gastrointestinal health of an animal increasing growth performance and treating osteopenia, osteoporosis and other bone disorders. | 2016-01-07 |
| 20160000731 | SORE-THROAT COMPOSITIONS AND RELATED METHODS - Methods for alleviating sore throat conditions and related compositions. In some such compositions, at least one non-hexose sugar alcohol and/or at least one non-hexose sugar alcohol precursor may be present in a concentration effective for reducing a concentration of sore-throat causing microorganisms in a patient's throat. The composition may further comprise at least one coating agent in a concentration effective for prolonging the presence of the at least one non-hexose sugar alcohol and/or at least one non-hexose sugar alcohol precursor in a patient's throat to treat the sore throat condition. | 2016-01-07 |
| 20160000732 | ORAL PHARMACEUTICAL COMPOSITIONS OF OSPEMIFENE - The present invention relates to pharmaceutical compositions comprising ospemifene or a pharmaceutically acceptable salt thereof having an average particle size of more than 20 microns and one or more pharmaceutically acceptable excipients comprising at least one solubility enhancing agent. The compositions of the invention may be advantageously used for the treatment or prevention of atrophy-related diseases or disorders in women, especially in women during or after the menopause. | 2016-01-07 |
| 20160000733 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY - The present invention is directed to pharmaceutical compositions of effective amounts of NMDA receptor antagonists and preservative for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neurotoxicity. The preferred NMDA receptor antagonist is ketamine. The preferred preservative is benzalkonium chloride. | 2016-01-07 |
| 20160000734 | METHOD AND COMPOSITIONS OF CIVAMIDE TO TREAT DISEASE OF THE INTESTINES - Compositions and a methods are described for treating disorders of the small and large bowel, such as Crohn's disease, ulcerative colitis and irritable bowel syndrome, without producing any treatment-related systemic side effects and with minimal or no abdominal discomfort. A method of administration of civamide that is incorporated into soft gelatin capsules and administered with meals is described. Surprisingly, the method provides for diminishment of pain and inflammation of the small and large bowel without producing any systemic side effects or significant abdominal discomfort. | 2016-01-07 |
| 20160000735 | METHODS FOR CLASSIFYING A CANCER AS SUSCEPTIBLE TO TMEPAI-DIRECTED THERAPIES AND TREATING SUCH CANCERS - The invention provides methods for classifying a cancer as susceptible to transmembrane prostate androgen induced (TMEPAI)-directed therapies, and methods for treating such cancers. The field of the invention pertains generally to medicine, pathology and oncology. More particularly, it addresses the treatment of breast cancer, such as triple-negative breast cancer, using a transmembrane prostate androgen induced (TMEPAI)-directed therapy. | 2016-01-07 |
| 20160000736 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS - The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease related disorders, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on baclofen and acamprosate combination. | 2016-01-07 |
| 20160000737 | TREATMENT OF PETS WITH SIRTUIN ACTIVATORS - The present invention provides for systems, compositions, methods and kits for regulating energy metabolism in pets. The systems, compositions, and kits can comprise, and methods can make use of, pet foods, pet treats, pet supplements, and pet drinks. In one aspect, the invention provides for pet food, treat, supplement, and drink compositions that comprise a combination of (a) leucine, and (b) a sirtuin activator, or any precursors or metabolites of (a) or (b). These combinations may be effective for reducing weight or adipose volume in the pet. In another aspect, the invention provides for methods of regulating energy metabolism by the administration of one or more compositions comprising leucine, a leucine metabolite, and/or a sirtuin activator. The invention also provides for kits comprising compositions of leucine, a leucine metabolite, and/or a sirtuin activator packaged in an oral dose form with usage instructions. | 2016-01-07 |
| 20160000738 | USE OF BUCILLAMINE IN THE TREATMENT OF GOUT - Disclosed are pharmaceutical compositions comprising, bucillamine, including bucillamine and allopurinol or colchicine, or pharmaceutically acceptable salts or solvates thereof, together with one or more pharmaceutically acceptable carriers, diluents and excipients. Methods for use of the said compositions in the treatment of gout and metabolic syndrome are also disclosed. | 2016-01-07 |
| 20160000739 | INTESTINAL TRACT-PROTECTING AGENT CONTAINING HYDROXYLATED FATTY ACID - The present invention provides an intestinal tract-protecting agent, an agent for the prophylaxis or improvement of a disease caused by damage in intestinal tract barrier function, which contains hydroxylated fatty acid, particularly hydroxylated unsaturated fatty acid, having a hydroxyl group at the 10-position and/or the 12-position, which is an intermediate of the metabolism of unsaturated fatty acid by | 2016-01-07 |
| 20160000740 | ENHANCED BIOAVAILABILITY OF POLYUNSATURATED FATTY ACIDS - Described herein are pharmaceutical compositions providing enhanced bioavailability of polyunsaturated fatty acids and methods of manufacturing the same. In particular, described herein are pharmaceutical compositions comprising soft enteric capsules that provide enhanced bioavailability of omega-3 polyunsaturated fatty acids. The oral pharmaceutical compositions described herein are useful as nutritional supplements or for the treatment of cardiovascular-related diseases, such as hyper dyslipidemia and moderate to high triglyceride levels. | 2016-01-07 |
| 20160000741 | Methods for Increasing Oral Osteogenesis Using Lipoxin A4 (LXA4) and Its Analogs - The invention provides methods for increasing oral osteogenesis using LXA | 2016-01-07 |
| 20160000742 | METHODS OF TREATING OTOTOXICITY - The present invention relates to use of DHA analogs and their pharmaceutical compositions for treating ototoxicity, by administering these compounds or pharmaceutical compositions to subjects in need thereof. Ototoxicity is defined as damage to the structures of the ear, such as the cochlea and vestibular system, by drugs or toxins. Ototoxicity can result in irreversible hearing loss, tinnitus, dysequilibrium, Meniere's disease, or vertigo. | 2016-01-07 |
| 20160000743 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OPHALMIC DISEASES AND DISORDERS - This invention provides compounds, methods and compositions for the treatment of ophthalmic diseases and disorders, including retinal and choroidal disorders and related conditions. More particularly, the invention provides a method of using the provided pharmaceutical compositions for the treatment of ophthalmic diseases and disorders, including retinal and choroidal diseases, and related conditions, upon topical administration to the eye. | 2016-01-07 |
| 20160000744 | Methods of Inhibiting IGF-1R Activation or Downtream Signalling Thereof to Reduce Radiation-Induced Cellular Senescence - Accelerated senescence has been shown to occur as a primary response to cellular stresses including DNA damaging agents (e.g., ionizing radiation) and is widely believed to be caused by continuous proliferative signaling in the presence of cell cycle arrest. The present disclosure provides a method of reducing cellular senescence in non-cancerous cells following exposure to ionizing radiation. The method comprises administering to a subject before, after, or concurrently with exposure to ionizing radiation an effective amount of a compound that inhibits activation of an insulin-like growth factor receptor (IGF-1R) or a compound that inhibits a protein involved in an IGF-1R induced signaling cascade. Also provided is a composition for use in reducing cellular senescence in non-cancerous cells following exposure to ionizing radiation, the composition comprising a compound that inhibits activation of an insulin-like growth factor receptor (IGF-1R) or a compound that inhibits a protein involved in an IGF-1R induced signaling cascade. | 2016-01-07 |
| 20160000745 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES - The present invention relates to compositions and kits including a chemical uncoupler, such as tyrphostin 9 or precursor or a salt thereof, and compositions including a chemical uncoupler, such as tyrphostin 9 in combination with one or more therapeutic agents, for example, L-carnitine, which are useful, for example, in treating obesity, preventing weight gain, promoting weight loss/slimming, and/or treating or preventing the development of diabetes. | 2016-01-07 |
| 20160000746 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION WITH MELATONIN ANALOGUES - Pharmaceutical compositions and methods for treating and/or preventing age-related macular degeneration with melatonin analogues are provided. | 2016-01-07 |
| 20160000747 | PRODUCT COMPRISING RED CLOVER EXTRACT AND METHODS FOR PRODUCING THE SAME - The invention relates to a composition comprising isoflavones from red clover. The red clover extract has been fermented to obtain a composition comprising aglycone isoflavones. The fermentation is preferably performed by a lactic acid bacteria or fermented dandelion extract. | 2016-01-07 |
| 20160000748 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS - The invention is a method and composition for treating a topical microbial infection in a subject. The method includes the step of administering a therapeutically effective amount of a polyether ionophore, or a therapeutically acceptable salt thereof, to the subject. | 2016-01-07 |
| 20160000749 | Method of Inhibiting or Treating a Dengue Virus Infection with Quercetin - The present invention relates to a composition having antiviral activity for prophylaxis or treatment of | 2016-01-07 |
| 20160000750 | COMBINATION OF EGCG OR METHYLATED EGCG AND A PDE INHIBITOR - Disclosed is a medicament characterized by the combination of: epigallocatechin gallate, methylated epigallocatechin gallate, or a pharmacologically permitted salt thereof; and a phosphodiesterase inhibitor. | 2016-01-07 |
| 20160000751 | METHOD FOR TREATING AND/OR DELAYING THE DEGENERATION OF PURKINJE CELLS - A method for treating and/or delaying the degeneration of Purkinje cells in a subject is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a medicament, wherein the medicament comprises a phthalide selected from the group consisting of n-butylidenephthalide (BP), a metabolic precursor of BP, a pharmaceutically acceptable salt of a metabolic precursor of BP, a pharmaceutically acceptable ester of a metabolic precursor of BP, and combinations thereof. | 2016-01-07 |
| 20160000752 | METHOD FOR INCREASING MUSCLE GROWTH BY BLOCKING SIRTUIN ACTIVITY - Systems and methods are described providing therapeutic preparations of sirtuin inhibitors, such as SIRT1 inhibitors, for stimulating load-induced skeletal muscle growth in the body of a patient. The natural stimulation of SIRT1 activity can be suppressed through increased caloric intake and loading in conjunction with the inhibition of sirtuin activity to improve the inhibitory effect. In addition, known muscle growth promoting agents such as amino acids and hormones can be administered at the same time as the sirtuin inhibitor. The size of the tissue structure to be treated or the body size may be used to determine the therapeutic dose of sirtuin inhibitor. The sirtuin inhibitor and muscle stimulating agents are either locally or systemically delivered at therapeutic doses for the desired effect. The SIRT1 inhibitor Splitomycin is particularly effective. | 2016-01-07 |
| 20160000753 | Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof - Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions. | 2016-01-07 |
| 20160000754 | Antiviral Activity from Medicinal Mushrooms and their Active Constituents - Compounds having unique antiviral properties found in mushroom mycelium and their analogs are extracted, concentrated, isolated or manufactured to create compositions useful in preventing the spread and proliferation of various viruses afflicting animals, particularly viruses harming humans, pigs, birds, bats and bees. Such compounds and compositions can be used individually or in combination with known medicines or natural products to improve health. | 2016-01-07 |
| 20160000755 | COMPOSITIONS AND METHODS TO IMPROVE ADOPTIVE CELL THERAPIES - Compositions and methods of enhancing the potency and efficacy of adoptive cell therapy using integrin-ligand stabilizers, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the effector cells ex vivo with agonists or stabilizers having the general Formula (I); methods of treating integrin-expressing cells with such stabilizers to enhance tumor infiltration; and therapeutic methods comprising administering stabilizer or agonist-treated cells to a mammal requiring treatment of solid tumors, hematologic cancers. | 2016-01-07 |
| 20160000756 | IMIDAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY - Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell. | 2016-01-07 |
| 20160000757 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS - There is presently provided methods for delivering an anti-fibrotic or anti-cancer agent to a cell. The methods comprise contacting a cell with an effective amount of imidazolium and imidazolinium compounds as described herein, including imidazolium and imidazolinium salts. | 2016-01-07 |
| 20160000758 | Chemical Compositions And Methods For Enhancing Transdermal Delivery Of Therapeutic Agents - The present application discloses chemical compositions and methods for enhancing the transdermal permeation of therapeutic agents through skin. The chemical compositions and methods of the invention can include combinations of a first fatty acid having about 14 or more carbon atoms and a second fatty acid having about 10 or less carbon atoms. These compositions are useful for the delivery of therapeutic agents, in particular hard to deliver drugs such as those that have fused rings, including ondansetron, and large drugs such as peptides. The compositions of the invention can be formulated as transdermal gels, lotions, creams, transdermal patches, sprays or mists. | 2016-01-07 |
| 20160000759 | FORMULATIONS OF BENDAMUSTINE - Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations. | 2016-01-07 |
| 20160000760 | ANTIVIRAL COMPOUNDS - The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection. | 2016-01-07 |
| 20160000761 | Formulation comprising benzothiazolone compound - The present invention relates to a pharmaceutical composition in solid oral dosage form comprising (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one acetate salt. | 2016-01-07 |
| 20160000762 | IMPROVING COGNITIVE FUNCTION - Provided herein, inter alia, are compounds useful in improving cognitive function, memory and learning in both healthy and diseased subjects. | 2016-01-07 |
| 20160000763 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS - The present invention discloses compounds of Formula (I): wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection. | 2016-01-07 |
| 20160000764 | NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS - The present invention relates to compounds of formula (I) | 2016-01-07 |
| 20160000765 | METHODS FOR TREATING BOWEL DISEASES - The present invention provides new methods of treating bowel disease (BD) by increasing a durability of response; treating BD in males; treating BD in adolescent subjects; treating bloating due to BD in males; and methods of maintaining remission of BD. | 2016-01-07 |
| 20160000766 | HDAC INHIBITORS TO TREAT CHARCOT-MARIE-TOOTH DISEASE - The present application relates to diseases in the peripheral nervous system, particularly hereditary neuropathies, most particularly, Charcot-Marie-Tooth (CMT) disease. It is shown that this disease is associated with decreased acetylated tubulin levels, which can be overcome by inhibition of histone deacetylases (HDACs). Using HDAC inhibitors, it is shown herein that the symptoms of the CMT phenotype can be overcome both in vitro and in vivo. Also provided herein are two different mouse models of CMT disease. | 2016-01-07 |
| 20160000767 | ANTIBACTERIAL COMPOUNDS - Provided are iminosugars having antibacterial properties and methods of treating and/or preventing bacterial infections with such iminosugars. The present disclosure relates to antibacterial compounds and, in particular, to iminosugars having antibacterial activity. One embodiment is a method of treating or preventing a bacterial infection comprising administering to a subject in need thereof an antibacterial effective amount of a compound of the following formula: or a pharmaceutically acceptable salt thereof. | 2016-01-07 |
| 20160000768 | CYCLOPROPYLAMINE INHIBITORS OF OXIDASES - The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I) as described and defined herein, and their use in therapy, including, e.g., the treatment or prevention of cancer. | 2016-01-07 |
| 20160000769 | METHODS AND DRUG PRODUCTS FOR TREATING ALZHEIMER'S DISEASE - Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype. | 2016-01-07 |
| 20160000770 | PHARMACEUTICAL COMPOUNDS AND USE OF SAME IN CANCER AND TAUOPATHIES - Disclosed are compounds of formula (1)-(V): where the substituents are as provided herein. Further disclosed are methods of inhibiting tau aggregation, treating or ameliorating a tauopathy or cancer by administration of such a compound. Tau is a microtubule-binding protein that accumulates in a number of neurodegenerative disorders, including frontotemporal dementia and Alzheimer's disease (AD). The presence of abnormal tau correlates with neuron loss and memory deficits in patients with AD and other neurodegenerative disorders that involve tau accumulation. | 2016-01-07 |
| 20160000771 | Inhibitors of Human Immunodeficiency Virus Replication - The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. | 2016-01-07 |
| 20160000772 | Methods of Using C-Met Modulators - Methods of treating cancer by administering a compound of Formula I, | 2016-01-07 |
| 20160000773 | LIQUID PHARMACEUTICAL FORMULATIONS OF PALONOSETRON - The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments. | 2016-01-07 |
| 20160000774 | TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND DIMETHYL FUMARATE - This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with DMF. This invention also provides a package comprising laquinimod and DMF for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with DMF in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides a pharmaceutical composition comprising laquinimod and DMF for use in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and DMF in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. | 2016-01-07 |
| 20160000775 | USE OF HIGH DOSE LAQUINIMOD FOR TREATING MULTIPLE SCLEROSIS - Disclosed herein are methods of treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome, methods for treating a human subject by providing neuroprotection to the human subject, and methods of treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome by increasing the time to confirmed disease progression, increasing the time to confirmed relapse or reducing brain atrophy in the human patient, comprising orally administering to the human patient or subject a daily dose of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof. The subject invention also provides a pharmaceutical oral unit dosage form of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier for use in treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome, for use in treating a human subject by providing neuroprotection to the human subject, or for use treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome by increasing the time to confirmed disease progression, increasing the time to confirmed relapse or reducing brain atrophy in the human patient. | 2016-01-07 |
| 20160000776 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2016-01-07 |
| 20160000777 | METHODS OF USING HISTAMINE RECEPTOR AGONISTS AND ANTAGONISTS - This invention relates to a transdermal drug formulation that includes a pharmaceutically suitable carrier; an effective amount of a therapeutic agent; and a histamine type 4 receptor (“H4R”) agonist, as well as a transdermal vaccine formulation that includes a pharmaceutically suitable carrier; an effective amount of an antigen or antigen-encoding nucleic acid molecule present in the carrier, and optionally one or more adjuvants; and an H4R agonist. The present invention also relates to transdermal delivery device including such formulations and methods of administering such formulations. The present invention also relates to methods of enhancing epithelial barrier formation in a patient involving administering to the patient at a site of epithelial disruption an amount of a formulation that comprises an H4R antagonist. The present invention also relates to a method of inhibiting pathogen infection or local spread of infection in the epithelia using an H4R antagonist, an H1R antagonist, or a combination thereof. | 2016-01-07 |
| 20160000778 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION - An exemplary embodiment relates to novel protein modulators capable of altering function of the mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction. An exemplary embodiment provides compositions, pharmaceutical preparations and methods of correcting the cellular alteration of a mutant CFTR protein wherein the CFTR mutation is a mutation ΔF508-CFTR, or another mutation of class II. | 2016-01-07 |
| 20160000779 | Compounds for Treatment of Fibrosis Diseases - The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of fibrosis. Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue in a reparative or reactive process. Fibrosis is the end result of chronic inflammatory reactions induced by a variety of stimuli including persistent infections, autoimmune reactions, allergic responses, chemical insults, radiation, and tissue injury. | 2016-01-07 |
| 20160000780 | Compounds for Treatment of Cancer - The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of cancer. | 2016-01-07 |
| 20160000781 | PHTHALAZINONE DERIVATIVES - Compounds of the formula (I): | 2016-01-07 |
| 20160000782 | PHARMACEUTICAL COMPOSITION CONTAINING ANTIBACTERIAL AGENT - [Problem] The purpose of the present invention is to provide a pharmaceutical composition containing an antibacterial agent, which is effective in elucidating one cause of dementia, and in treatment thereof. | 2016-01-07 |
| 20160000783 | Trk-INHIBITING COMPOUND - The present invention provides a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for Trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. | 2016-01-07 |
| 20160000784 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS - Compounds of the general formula (I) and salts thereof are useful in the treatment of diseases associated with aberrant activity of the protein kinases IKKε and/or TBK-1 in which one of V and W is N, and the other of V and W is C—H; and R | 2016-01-07 |
| 20160000785 | Novel Imidazole Amines as Modulators of Kinase Activity - The invention provides novel imidazole amine compounds according to Formula (I) and Formula (II) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. | 2016-01-07 |
| 20160000786 | Medicinal Drug with Activity against Gram Positive Bacteria, Mycobacteria and Fungi - The present invention discloses a nanocomposite material having single-walled aluminosilicate nanotube in polymer, a membrane comprising such nanocomposite material, and the method of making the nanocomposite material, in which the composite material has high volume fraction of well-dispersed nanotubes. A gel-phased single-walled aluminosilicate nanotube is first prepared and then mixed with a polymer matrix to yield the composite material. | 2016-01-07 |
| 20160000787 | INHIBITORS OF CDK8/19 FOR USE IN TREATING ESTROGEN RECEPTOR POSITIVE BREAST CANCER - The invention provides a selective inhibitor of CDK8/19 for use in a method of treating a patient having estrogen receptor positive (ER+) breast cancer, including breast cancer that is resistant to antiestrogen therapy. In some embodiments, the selective inhibitor of CDK8/19 is administered in combination with antiestrogen therapy. In some embodiments, the selective inhibitor of CDK8/19 is administered to ER+HER2+ breast cancer patients in combination with HER2-targeting drugs. | 2016-01-07 |
| 20160000788 | USE OF ITK INHIBITORS FOR THE TREATMENT OF CANCER - This invention relates generally to the use of ITK (IL-2 inducible T-cell kinase) inhibitors for the treatment of patients who have melanoma or other solid tumors. Applicants demonstrate that ITK lentiviral small hairpin RNA knockdowns and a small molecule inhibitor can each decrease the proliferation and migration of melanoma cell lines and a small molecule inhibitor can be used to inhibit the growth of melanomas in vivo. | 2016-01-07 |
| 20160000789 | MTOR MODULATORS AND USES THEREOF - The present invention provides methods and compositions for selective modulation of certain protein kinases, and especially mTor complexes. The methods and compositions are particularly useful in inhibiting mTor selectively for therapeutic applications. | 2016-01-07 |
| 20160000790 | DRUG COMBINATION - The invention provides a composition which comprises (a) a PDE3/PDE4 inhibitor which is 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (b) a muscarinic receptor antagonist. | 2016-01-07 |
| 20160000791 | PAR1 MODULATION TO ALTER MYELINATION - Materials and methods for modulating protease activated receptor 1 (PAR1) activity to alter myelination are provided. | 2016-01-07 |
| 20160000792 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS - Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors. | 2016-01-07 |
| 20160000793 | SODIUM CHANNEL BLOCKER FOR TREATMENT OF LOSS OF SUPERFICIAL SENSITIVITY - The invention concerns a sodium channel blocker for the treatment of a reduction or loss of superficial sensitivity or sense of touch of a human being or another mammal | 2016-01-07 |
| 20160000794 | METHODS FOR THE DIAGNOSIS AND TREATMENT OF SJOGREN'S SYNDROME - The finding that patients with Sjögren's syndrome exhibit a statistically significant increase in expression of BMP6 in the salivary gland, relative to healthy control subjects, is described. Also described is the finding that overexpression of BMP6 in the salivary glands of mice results in an increase in electrical potential across the salivary gland. Methods of diagnosing a subject as having Sjögren's syndrome, or at risk for developing Sjögren's syndrome, by measuring the level of BMP6 expression in a salivary gland of a subject, measuring electrical potential in a salivary gland of a subject, or both, are described. Methods of treating a subject with Sjögren's syndrome, or methods of increasing salivary flow in a subject, by administering an agent that inhibits BMP6 expression or activity are also described. The use of XIST and MECP2 as diagnostic and therapeutic targets for male Sjögren's syndrome patients is further described. | 2016-01-07 |
| 20160000795 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS - This invention relates to methods of treating B-cell malignancies using a combination of inhibitors of JAK1 and/or JAK2 and inhibitors of PI3Kδ. | 2016-01-07 |
| 20160000796 | PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTION OR TREATMENT OF CANCER - Abacavir, a nucleoside analogue reverse transcriptase inhibitor, has been found to exhibit an anti-cancer activity on ATL cells in vitro without inhibiting DNA replication of normal cells. Abacavir or a pharmaceutically acceptable derivative thereof is useful as an active ingredient of a pharmaceutical composition for use in the prevention or the treatment of cancer, in particular a cancer whose DNA repair system is impaired such as breast cancer or adult T-cell leukemia. | 2016-01-07 |
| 20160000797 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS - The present disclosure provides compositions and methods for the prevention of HSV infection in an HSV seronegative individual. | 2016-01-07 |
| 20160000798 | USES OF DPP IV INHIBITORS - The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments. | 2016-01-07 |
| 20160000799 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS - The present application discloses a pharmaceutical composition comprising a class of cholesteryl ester transfer protein (CETP) inhibitors with improved oral bioavailability. The application further discloses compositions comprising a class of CETP inhibitor and at least one surfactant in the form of a solution, suspension, emulsion or a pre-concentrate. | 2016-01-07 |
| 20160000800 | MODULATORS AND METHODS FOR THE TREATMENT OF ROSACEA - An in vitro method of screening candidate compounds for the preventive or curative treatment of rosacea is described. The method can include determining the capacity of a compound to modulate the expression or activity of the Transient Receptor Potential (TRPs), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of rosacea. The method can also include in vitro diagnosis or prognosis of this pathology. | 2016-01-07 |
| 20160000801 | SUSPENSION FOR ORAL ADMINISTRATION COMPRISING AMORPHOUS TOLVAPTAN - This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. | 2016-01-07 |
| 20160000802 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN - Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions. | 2016-01-07 |
| 20160000803 | PHARMACEUTICAL COMPOSITION FOR TRANSMUCOSAL ADMINISTRATION OF BENZODIAZEPINES - The current application relates to a liquid pharmaceutical composition for intraoral transmucosal administration of a benzodiazepine drug to a mammal. The composition comprises a physiologically acceptable hydrophobic phase, an eutectic mixture of benzodiazepine compound providing high solubility of the benzodiazepine in said hydrophobic phase, at least one physiologically acceptable organic solvent and at least one physiologically acceptable surfactant. | 2016-01-07 |
| 20160000804 | INHIBITORS OF NA(V) 1.9 CHANNEL ACTIVITY AND USES THEREOF FOR TREATING PAIN - The present invention relates to novel compounds for use for preventing, alleviating or treating pain in a subject. Also herein described are pharmaceutical compositions, their preparation and uses as well as methods for preventing, alleviating or treating pain using such compounds and compositions. | 2016-01-07 |
| 20160000805 | USE AND APPLICATION REGIMEN OF A PHARMACEUTICAL COMPOSITION CONTAINING LEVONORGESTREL AND A COX INHIBITOR FOR ON-DEMAND CONTRACEPTION - The invention relates to a method of hormonal female controlled “on demand” contraception, in which a pharmaceutical preparation comprising a COX inhibitor and levonorgestrel is taken on demand prior to expected sexual intercourse. Further subjects of the invention relate to pharmaceutical compositions and application regimes for “on demand” contraception. | 2016-01-07 |
| 20160000806 | PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME - A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided. | 2016-01-07 |
